Truncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancer

截短的O-聚糖依赖性机制诱导胰腺癌转移扩散

基本信息

项目摘要

Pancreatic cancer (PC) is the fourth leading cause of cancer death and often goes undiagnosed until it has already advanced and metastasized. Aberrant changes in O-glycans, such as increased expression of truncated carbohydrate antigens (Tn, sialylated Tn/STn), are commonly observed in PC. However, the mechanistic involvement of these truncated O-glycan structures in PC progression and metastasis is under-explored. Hence, our study is focused on investigating the mechanistic role of truncated O-glycans during early metastatic dissemination in PC. The O-glycosyltransferase Core 1 β1,3-Galactosyltransferase (C1GALT1) catalyzes the second step of mucin-type O-glycan biosynthesis by adding galactose to the first sugar N-acetylgalactosamine (Tn) that forms the Core 1 carbohydrate structure. Such structures are usually elongated to mature O-glycans found on normal tissue, but their extension may be truncated at the Tn-glycan stage during cancer due to inactive C1GALT1 activity. Our preliminary data demonstrated the loss of O-glycosyltransferase activity, C1GALT1, in a subset of (poorly differentiated) human PC tissue. Further, CRISPR/Cas9-based C1GALT1 knockout (KO) in PC cells resulted in aberrant O-glycosylation (increased Tn and STn glycans). Along with glycan alterations presented upon oncogenic glycoproteins (mucin glycoproteins and cancer stem cell markers), our studies also indicate increased tumorigenicity and metastasis of C1GALT1 KO PC cells. We have also observed O-glycan truncation present on CD44, a cancer stem cell marker, in C1GALT1 models. Interestingly, knockout of C1galt1 along with KrasG12D and Trp53R172H/+ mutations in mouse models resulted in early-onset (in 3 weeks) and early distant metastasis (in 10 weeks) of PC. Based on these observations, our major goal is to investigate the mechanistic role of truncated O-glycans in PC progression and metastasis. Based on these observations, we hypothesize that "Truncated O-glycans on cancer-associated glycoproteins (mucins and stemness markers) induce the early onset of progression and metastatic dissemination in pancreatic cancer." To test this hypothesis, the following aims are proposed. The first aim will investigate the functional impact of C1GALT1 expression and aberrant glycosylation profile on cancer-associated glycoproteins in pancreatic cancer. The second aim will elucidate how truncated O-glycans (such as Tn and STn) on membrane-bound mucins and stemness markers facilitate pancreatic cancer metastasis. The third aim will determine, in vivo, the impact of truncated O-glycans in the early onset of pancreatic cancer metastasis using C1galt1 knockout KC and KPC mice. The proposed studies will establish the association of aberrant expression of truncated Tn and STn glycans with differential membrane- bound mucin function during PC progression and metastasis. This study will significantly contribute to our knowledge of mucin glycobiology in cancer. Altogether, this proposed study will also pave the way for developing novel therapeutics for modulating membrane-bound mucin function in PC.
胰腺癌(PC)是导致癌症死亡的第四大原因,通常直到确诊后才被诊断出来。 晚期和转移。O-葡聚糖的异常变化,如截短的表达增加 糖类抗原(TN,唾液酸化的TN/STN)常见于PC。然而,机械论 这些截短的O-糖链结构在前列腺癌进展和转移中的作用还没有得到充分的研究。因此, 我们的研究集中在研究截短的O-糖链在早期转移中的机制作用。 在PC上传播。O-糖基转移酶核心1β1,3-半乳糖基转移酶(C1GALT1)催化 在第一糖N-乙酰半乳糖胺中加入半乳糖生物合成粘液型O-葡聚糖的第二步 (TN)形成核心1碳水化合物结构。这种结构通常被拉长为成熟的O-葡聚糖 在正常组织中发现,但在癌症期间,由于不活跃,它们的延伸可能在TN-多糖阶段被截断 C1GALT1活性。我们的初步数据显示,O-糖基转移酶活性C1GALT1在 (低分化的)人类PC组织的子集。此外,PC中基于CRISPR/Cas9的C1GALT1基因敲除(KO) 细胞产生异常的O-糖基化(TN和STN糖链增加)。伴随着糖链的变化 在致癌糖蛋白(粘蛋白糖蛋白和癌症干细胞标记物)上,我们的研究也表明 C1GALT1 KO PC细胞成瘤性和转移性增强。我们还观察到O-葡聚糖的截断 在C1GALT1模型中,存在于肿瘤干细胞标记物CD44上。有趣的是,C1galt1和 KrasG12D和Trp53R172H/+突变导致小鼠早期发病(3周内)和早期远处 PC转移(10周内)。基于这些观察,我们的主要目标是研究 截短型O-糖链在前列腺癌进展和转移中的作用。基于这些观察结果,我们假设 癌症相关糖蛋白(粘蛋白和茎干标志物)上的截短O-糖链诱导早期 胰腺癌进展和转移扩散的开始。为了验证这一假说,以下是 提出了目标。第一个目的是研究C1GALT1的表达和异常对功能的影响 胰腺癌中肿瘤相关糖蛋白的糖基化特征。第二个目标将阐明如何 膜结合粘蛋白和茎标记上的截短O-糖链(如TN和STN)有助于 胰腺癌转移。第三个目标将在体内确定截短的O-葡聚糖在早期的影响 用C1galt1基因敲除KC和KPC小鼠研究胰腺癌转移。拟议的研究将 建立截短的TN和STN糖链的异常表达与差异膜- 结合粘蛋白在前列腺癌进展和转移中的作用。这项研究将对我们的 癌症中的粘蛋白糖生物学知识。总之,这项拟议的研究也将为发展 调节PC膜结合粘蛋白功能的新疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Surinder K. Batra其他文献

Functions of tumorigenic and migrating cancer progenitor cells in cancer progression and metastasis and their therapeutic implications
  • DOI:
    10.1007/s10555-007-9052-4
  • 发表时间:
    2007-02-02
  • 期刊:
  • 影响因子:
    8.700
  • 作者:
    Murielle Mimeault;Surinder K. Batra
  • 通讯作者:
    Surinder K. Batra
Wolfram 症候群の実態調査
关于 Wolfram 综合征的事实调查
  • DOI:
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Yukihiro Tamura;Michiyo Higashi;Sho Kitamoto;Seiya Yokoyama;Masahiko Osako;Michiko Horinouchi;Takeshi Shimizu;Mineo Tabata;Surinder K. Batra;Masamichi Goto;Suguru Yonezawa;松永仁恵,田部勝也,太田康晴,奥屋 茂,和田安彦,山田祐一郎,雨宮 伸,杉原茂孝,岡 芳知,谷澤幸生
  • 通讯作者:
    松永仁恵,田部勝也,太田康晴,奥屋 茂,和田安彦,山田祐一郎,雨宮 伸,杉原茂孝,岡 芳知,谷澤幸生
PP01.05 Targeting MUC16-Mediated KRASi Resistance in NSCLC
PP01.05 针对非小细胞肺癌中 MUC16 介导的 KRASi 耐药性
  • DOI:
    10.1016/j.jtho.2025.03.013
  • 发表时间:
    2025-04-01
  • 期刊:
  • 影响因子:
    20.800
  • 作者:
    Ashu Shah;Shamema Salam;Sanjib Chaudhary;Iniyan A. Muthamil;Imayavaramban Lakshmanan;Surinder K. Batra;Apar K. Ganti
  • 通讯作者:
    Apar K. Ganti
Mo1138 COMPARATIVE PROTEOMICS REVEALS TRANSLATIONAL POTENTIAL OF TARGETS FOR PANCREATIC DUCTAL ADENOCARCINOMA
  • DOI:
    10.1016/s0016-5085(23)02780-4
  • 发表时间:
    2023-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Mathilde Resell;Hanne-Line Rabben;Manoj Amrutkar;Lars Hagen;Surinder K. Batra;Caroline S. Verbeke;Timothy C. Wang;Duan Chen;Chun-Mei Zhao
  • 通讯作者:
    Chun-Mei Zhao
MUC5AC in stromal heterogeneity and the Progression of Pancreatic Cancer
  • DOI:
    10.1016/j.canlet.2023.216541
  • 发表时间:
    2024-01-28
  • 期刊:
  • 影响因子:
  • 作者:
    Surinder K. Batra
  • 通讯作者:
    Surinder K. Batra

Surinder K. Batra的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Surinder K. Batra', 18)}}的其他基金

Molecular Imaging Probe(s) for Optical Surgical Navigation of Pancreatic Cancer
用于胰腺癌光学手术导航的分子成像探针
  • 批准号:
    10557180
  • 财政年份:
    2022
  • 资助金额:
    $ 50.35万
  • 项目类别:
Novel Therapy to Inhibit IPMN Progression
抑制 IPMN 进展的新疗法
  • 批准号:
    10446455
  • 财政年份:
    2022
  • 资助金额:
    $ 50.35万
  • 项目类别:
Molecular Imaging Probe(s) for Optical Surgical Navigation of Pancreatic Cancer
用于胰腺癌光学手术导航的分子成像探针
  • 批准号:
    10367553
  • 财政年份:
    2022
  • 资助金额:
    $ 50.35万
  • 项目类别:
Novel Therapy to Inhibit IPMN Progression
抑制 IPMN 进展的新疗法
  • 批准号:
    10640955
  • 财政年份:
    2022
  • 资助金额:
    $ 50.35万
  • 项目类别:
Connectivity mapping identified novel combination therapy for glioblastoma
连接映射确定了胶质母细胞瘤的新型联合疗法
  • 批准号:
    10504826
  • 财政年份:
    2022
  • 资助金额:
    $ 50.35万
  • 项目类别:
Connectivity mapping identified novel combination therapy for glioblastoma
连接映射确定了胶质母细胞瘤的新型联合疗法
  • 批准号:
    10686268
  • 财政年份:
    2022
  • 资助金额:
    $ 50.35万
  • 项目类别:
Truncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancer
截短的O-聚糖依赖性机制诱导胰腺癌转移扩散
  • 批准号:
    10503433
  • 财政年份:
    2022
  • 资助金额:
    $ 50.35万
  • 项目类别:
Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer
用于胰腺癌早期诊断和风险评估的尿液和血清生物标志物
  • 批准号:
    10156494
  • 财政年份:
    2021
  • 资助金额:
    $ 50.35万
  • 项目类别:
Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer
用于胰腺癌早期诊断和风险评估的尿液和血清生物标志物
  • 批准号:
    10339431
  • 财政年份:
    2021
  • 资助金额:
    $ 50.35万
  • 项目类别:
Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer
用于胰腺癌早期诊断和风险评估的尿液和血清生物标志物
  • 批准号:
    10551280
  • 财政年份:
    2021
  • 资助金额:
    $ 50.35万
  • 项目类别:

相似海外基金

Impact of N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B) on the Progression of Melanoma
N-乙酰半乳糖胺-4-硫酸酯酶(芳基硫酸酯酶 B)对黑色素瘤进展的影响
  • 批准号:
    10399551
  • 财政年份:
    2021
  • 资助金额:
    $ 50.35万
  • 项目类别:
Impact of N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B) on the Progression of Melanoma
N-乙酰半乳糖胺-4-硫酸酯酶(芳基硫酸酯酶 B)对黑色素瘤进展的影响
  • 批准号:
    10664841
  • 财政年份:
    2021
  • 资助金额:
    $ 50.35万
  • 项目类别:
Impact of N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B) on the Progression of Melanoma
N-乙酰半乳糖胺-4-硫酸酯酶(芳基硫酸酯酶 B)对黑色素瘤进展的影响
  • 批准号:
    10258903
  • 财政年份:
    2021
  • 资助金额:
    $ 50.35万
  • 项目类别:
Novel Dried Blood Spot Mass Spectrometry Functional Assays for Lysosomal Acid Lipase and N-acetylgalactosamine-sulfate Sulfatases for Use in Newborn Screening
用于新生儿筛查的溶酶体酸性脂肪酶和 N-乙酰半乳糖胺硫酸酯硫酸酯酶的新型干血斑质谱功能分析
  • 批准号:
    9238498
  • 财政年份:
    2015
  • 资助金额:
    $ 50.35万
  • 项目类别:
SYNTHESIS OF N-ACETYLGALACTOSAMINE IN ENCYSTING GIARDIA
包囊贾第鞭毛虫中 N-乙酰半乳糖胺的合成
  • 批准号:
    3436813
  • 财政年份:
    1991
  • 资助金额:
    $ 50.35万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了